Vaccine Response Impaired Clinical Trial
Official title:
A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination
The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?
The study is divided into two sub-studies. The first sub-study (BCG re-challenge) is an experimental medicine study in 168 healthy participants to determine if depletion of the gut microbiota leads to impaired BCG-induced protection against a subsequent Mycobacterium bovis BCG intradermal challenge. The second sub-study (Yellow Fever vaccine) has a very similar experimental design to the first but will determine if depletion of the gut microbiota leads to impaired BCG-induced protection against other infections. To assess this, participants in this sub-study (n=180) will be re-challenged after 3 months with a live attenuated viral vaccine, the Yellow Fever vaccine, which induces a mild viremia. In both sub-studies, participants will initially be randomised to receive a 3 day course of antibiotics or none (comparator group). The two groups in each sub-study will be randomised again to receive either BCG vaccine or 0.9% NaCl placebo injection in the left arm. BCG re-challenge sub-study (Sub-study 1): Six months following randomisation, all participants will receive a BCG vaccine challenge in the right arm. A punch skin biopsy will be taken of this challenge site 2 weeks after the challenge to assess M. bovis BCG bacterial load in the skin. Yellow Fever vaccine sub-study (Sub-study 2): Three months following randomisation, all participants will receive a Yellow Fever vaccine challenge in the right arm. Blood samples will be collected from Yellow Fever vaccinated participants at day 3, 5 and 7 following Yellow Fever vaccine challenge to quantify Yellow Fever viral load in blood. All participants in both sub-studies will have blood samples collected at randomisation, before each vaccination, 2 weeks after each BCG vaccination and in the Yellow Fever vaccine sub-study at day 3, 5 and 7 following Yellow Fever vaccination. Stool samples will be collected prior to randomisation, and prior to each vaccination. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
Active, not recruiting |
NCT01446978 -
Three Doses of Hepatitis A Vaccine in Patients With Immunomodulating Drugs
|
Phase 2 | |
Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
Not yet recruiting |
NCT05923970 -
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
|
||
Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
Completed |
NCT03467074 -
Role of Interferon-λ and Vaccine Response
|
||
Completed |
NCT05124509 -
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
|
||
Completed |
NCT05791851 -
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
|
||
Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
Completed |
NCT03930017 -
Pregnancy, Arsenic and Immune Response
|
||
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Completed |
NCT03368495 -
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
|
Phase 4 | |
Completed |
NCT04059991 -
Antibodies in Repeated Influenza Vaccination (ARIVA) Study
|
||
Completed |
NCT04912661 -
Iron and Vaccine Response
|
N/A | |
Completed |
NCT04915820 -
Iron and COVID-19 Vaccine Response
|
N/A | |
Completed |
NCT04885907 -
Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients
|
Phase 4 | |
Completed |
NCT03588013 -
Study of Environmental Enteropathy and Malnutrition in Pakistan
|
N/A | |
Completed |
NCT04936997 -
Immune Response to the COVID-19 Vaccine
|
Early Phase 1 | |
Completed |
NCT03996538 -
Vaccination Efficacy With Metformin in Older Adults
|
Phase 1 | |
Completed |
NCT02453113 -
Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment
|
N/A |